Rotavirus is a leading cause of severe diarrhoea in young children. The virus spreads easily through the faecal–oral route. Infants and children under five face the highest risk. Without good care, rapid fluid loss can become life-threatening.
The illness often starts suddenly. Watery stools, vomiting, and fever appear together. Dehydration then follows. Antibiotics do not treat this infection. Supportive care with fluids remains the first step. Prevention, therefore, matters as much as treatment.
Before routine immunization, rotavirus filled many paediatric wards in India. Studies found the virus in a large share of children admitted with diarrhoea. The country also carried a heavy share of global rotavirus deaths in children under five. Crowded homes, uneven sanitation, and delayed rehydration raised the danger.
Oral rotavirus vaccines changed that picture. India added the vaccine to the Universal Immunization Programme in 2016. The rollout began in a few states. It then expanded nationwide by 2019. Two Indian-made vaccines, Rotavac and Rotasiil, support this programme. Infants receive the drops with other routine shots.
Real-world studies later measured the effect. Hospital surveillance showed a clear fall in rotavirus-positive diarrhoea after introduction. In one large multi-hospital analysis, positivity among admitted children dropped from about 40% to about 20%. Three doses of Rotavac showed around 54% protection against severe rotavirus gastroenteritis. That result matched earlier trial findings.
Other analyses pointed in the same direction. Models estimated fewer cases and fewer deaths in children under five after vaccination scaled up. Antibiotic use linked to rotavirus illness also declined in some estimates. This matters because viral diarrhoea does not need antibiotics. Fewer unnecessary drugs can slow resistance.
The vaccine does not block every infection. Mild illness can still occur. Protection is stronger against severe disease and hospital admission than against all diarrhoea. Coverage also remains uneven. A missed dose leaves a child less protected. Cold-chain gaps and delayed visits still limit full benefit in some districts.
Genotypes continue to circulate. G3P[8] and other strains appear in post-vaccine samples. Surveillance teams watch this mix. So far, the programme still reduces severe disease, including illness from strains not fully matched to the vaccine.
Immunization works best with other measures. Clean water, handwashing, and early oral rehydration save children who still fall ill. Hospitals need to keep testing so the country can see which strains remain. Parents need clear advice that the drops prevent the worst cases, not every loose stool.
Rotavirus diarrhoea has not disappeared. It has become less deadly where vaccination coverage is high. India’s experience shows a practical lesson. A public vaccine, given on time in infancy, can cut hospital burden and child deaths. The next task is simple and hard at once. Reach every infant. Keep surveillance honest. Treat dehydration early when infection still breaks through.